183 related articles for article (PubMed ID: 26763180)
1. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients.
Odler B; Cseh Á; Constantin T; Fekete G; Losonczy G; Tamási L; Benke K; Szilveszter B; Müller V
Clin Respir J; 2017 Nov; 11(6):942-950. PubMed ID: 26763180
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary involvement in Fabry disease: overview and perspectives.
Franzen D; Krayenbuehl PA; Lidove O; Aubert JD; Barbey F
Eur J Intern Med; 2013 Dec; 24(8):707-13. PubMed ID: 23726861
[TBL] [Abstract][Full Text] [Related]
4. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of pulmonary function in Fabry disease: A bi-center observational study.
Franzen DP; Nowak A; Haile SR; Mottet D; Bonani M; Dormond O; Kohler M; Krayenbuehl PA; Barbey F
PLoS One; 2017; 12(7):e0180437. PubMed ID: 28742806
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary involvement in Fabry's disease.
Koskenvuo JW; Kantola IM; Nuutila P; Knuuti J; Parkkola R; Mononen I; Hurme S; Kalliokoski R; Viikari JS; Wendelin-Saarenhovi M; Kiviniemi TO; Hartiala JJ
Acta Cardiol; 2010 Apr; 65(2):185-92. PubMed ID: 20458826
[TBL] [Abstract][Full Text] [Related]
8. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
[TBL] [Abstract][Full Text] [Related]
9. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
10. Natural history of the respiratory involvement in Anderson-Fabry disease.
Magage S; Lubanda JC; Susa Z; Bultas J; Karetová D; Dobrovolný R; Hrebícek M; Germain DP; Linhart A
J Inherit Metab Dis; 2007 Oct; 30(5):790-9. PubMed ID: 17619837
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
[TBL] [Abstract][Full Text] [Related]
12. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
[TBL] [Abstract][Full Text] [Related]
13. Thyroid function in Fabry disease before and after enzyme replacement therapy.
Faggiano A; Severino R; Ramundo V; Russo R; Vuolo L; Del Prete M; Marciello F; Lombardi G; Cianciaruso B; Colao A; Pisani A
Minerva Endocrinol; 2011 Mar; 36(1):1-5. PubMed ID: 21460782
[TBL] [Abstract][Full Text] [Related]
14. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
15. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
16. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.
Lenders M; Hennermann JB; Kurschat C; Rolfs A; Canaan-Kühl S; Sommer C; Üçeyler N; Kampmann C; Karabul N; Giese AK; Duning T; Stypmann J; Krämer J; Weidemann F; Brand SM; Wanner C; Brand E
Orphanet J Rare Dis; 2016 Jun; 11(1):88. PubMed ID: 27356758
[TBL] [Abstract][Full Text] [Related]
18. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation.
Pietilä-Effati P; Söderström J; Saarinen JT; Löyttyniemi E; Kantola I
Mol Genet Genomic Med; 2022 May; 10(5):e1915. PubMed ID: 35246967
[TBL] [Abstract][Full Text] [Related]
20. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
